Zai Lab to Announce Full Year 2018 Financial Results Read more about Zai Lab to Announce Full Year 2018 Financial Results
Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference Read more about Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board Read more about Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board
Priority Review Granted to Zai Lab's NDA Application for ZEJULA (Niraparib) in China Read more about Priority Review Granted to Zai Lab's NDA Application for ZEJULA (Niraparib) in China
Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China Read more about Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China
Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme Read more about Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme
Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference Read more about Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference
Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA Read more about Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China Read more about MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
Zai Lab and Novocure Awarded Deal of the Year Read more about Zai Lab and Novocure Awarded Deal of the Year